Resveratrol has been shown to improve glycaemic control in humans [1]. Animal studies have shown similar beneficial effects of resveratrol [2] by increasing insulin secretion or enhancing sensitivity to insulin in peripheral organs via activation of SirT1 [3]. Recently, several reports described the ability of pancreatic α-cells to de-differentiate into insulin-producing cells after β-cell loss [4–6]. These findings raise the possibility for new diabetic therapies that exploit α-cell plasticity. In this study, we show that resveratrol can induce expression of several β-cell genes and insulin expression in pancreatic α-cells. Our results shed light on resveratrol action in α-cells and expand our understanding of its anti-diabetic effects.
Resveratrol induces re-expression of insulin and other pancreatic β-cell genes in a SirT1-dependent manner
αTC9 is a subclone selected for high glucagon expression and virtually no insulin expression [7]. Surprisingly, resveratrol significantly increased the expression of mouse Ins2 mRNA in a SirT1-dependent mechanism in these cells after 24 hr of treatment (Figure 1A, B) while glucagon mRNA was not significantly altered (Figure 1A). Next, we examined the expression of other β-cell markers (Ngn3, NeuroD1, Nkx6.1, FoxO1 and Pdx1) that regulate pancreatic β-cell differentiation and insulin gene transcription in α-cells. Interestingly, resveratrol increased expression of key β-cell transcription factors such as Pdx1 as well as Ngn3, NeuroD1, Nkx6.1 and FoxO1 (Figure 1C). Similar to its effect on insulin expression, resveratrol’s induction of Pdx1 was found to be SirT1-dependent whereas Ngn3 expression did not depend upon SirT1 (Figure 1D).
Re-expression of insulin gene by resveratrol in α-cells is enhanced by HDAC inhibition
Earlier studies of Pdx1 showed that it induced histone acetylation at the insulin promoter [8]. Therefore we performed ChIP-qPCR for acetylated histone H3 and H4, spanning the enhancer binding site of Pdx1 in the insulin promoter region. Our results showed a significant increase in H3 and H4 acetylation after resveratrol treatment, which was further enhanced by the co-administration of a HDAC inhibitor, Trichostatin A (TSA) (Figure 2A). This increase in promoter acetylation also correlated with increased transcription of the insulin gene (Figure 2B). We used rat INS-1cells (pancreatic β-cell line) to see the effect of resveratrol and TSA on insulin gene. Interestingly, we observed little or no induction of insulin gene expression by resveratrol and/or TSA in a β-cell line (Figure 2C). This finding suggests that resveratrol and HDAC inhibitors may be more effective in inducing insulin in heterologous cells where it is normally repressed. To validate increased insulin protein expression, RIA was used to quantify the insulin content in α-cells. Although no significant increase in intracellular insulin protein was detectable in resveratrol- or TSA-treated cells (data not shown), there was a significant increase in insulin protein after resveratrol and TSA co-treatment (Figure 2C).
Resveratrol has emerged as a promising anti-diabetic agent that exhibits significant ability to lower serum glucose in diabetic patients [2]. Recent experiments in genetically-manipulated mice have established that α-cells can directly trans-differentiate into β-cells under certain conditions such as β-cell loss in lineage-traced mice [4]. While the induction of β-cell genes such as Pdx1 can lead to insulin expression in α-cells [8, 9], cell transformation leading to expression of β-cell genes is another potential strategy to increase insulin production [5]. In this regard, several new drugs are being developed that modulate α-cell plasticity [10]. Our observation that resveratrol was able to induce insulin synthesis in α-cells is germane since it currently is undergoing clinical trials for treatment of type 2 diabetes.
The insulin-inducing effect on α-cells by resveratrol was SirT1-dependent. Furthermore, the induction of Pdx1 by resveratrol and the accompanying epigenetic changes on the insulin promoter suggests that it may have a broader reprogramming action than mere stabilization of low abundance insulin mRNA in these cells. In this connection, using an HDAC inhibitor in combination with resveratrol further enhanced insulin induction at both the mRNA and protein levels. In summary, our findings demonstrating the effects of resveratrol on α-cell plasticity provide a new understanding of its anti-diabetic actions and point towards novel treatment strategies for diabetes.